Cited by 230Psychedelics and Drug StudiesTreatment of Major DepressionTryptophan and brain disorders

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Open access

Roseman, Leor, Demetriou, Lysia, Wall, Matthew B., Nutt, David J., Carhart-Harris, Robin L.·2018·Neuropharmacology

DOI 10.1016/j.neuropharm.2017.12.041

Open this paper in CoChat — free account Open PDF

Abstract

Recent evidence indicates that psilocybin with psychological support may be effective for treating depression. Some studies have found that patients with depression show heightened amygdala responses to fearful faces and there is reliable evidence that treatment with SSRIs attenuates amygdala responses (Ma, 2015). We hypothesised that amygdala responses to emotional faces would be altered post-treatment with psilocybin. In this open-label study, 20 individuals diagnosed with moderate to severe, treatment-resistant depression, underwent two separate dosing sessions with psilocybin. Psychological support was provided before, during and after these sessions and 19 completed fMRI scans one week prior to the first session and one day after the second and last. Neutral, fearful and happy faces were presented in the scanner and analyses focused on the amygdala. Group results revealed rapid and enduring improvements in depressive symptoms post psilocybin. Increased responses to fearful and happy faces were observed in the right amygdala post-treatment, and right amygdala increases to fearful versus neutral faces were predictive of clinical improvements at 1-week. Psilocybin with psychological support was associated with increased amygdala responses to emotional stimuli, an opposite effect to previous findings with SSRIs. This suggests fundamental differences in these treatments' therapeutic actions, with SSRIs mitigating negative emotions and psilocybin allowing patients to confront and work through them. Based on the present results, we propose that psilocybin with psychological support is a treatment approach that potentially revives emotional responsiveness in depression, enabling patients to reconnect with their emotions. TRIAL REGISTRATION: ISRCTN, number ISRCTN14426797. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.12.041

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Advances in functional and structural MR image analysis and implementation as FSL
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.07.051 · Cited by 13,630
Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation
Beck, A. T., Steer, R. A., & Carbin, M. G. (1988) · Clinical Psychology Review · doi:10.1016/0272-7358(88)90050-5 · Cited by 11,696
AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages
Cox, R. W. (1996) · Computers and Biomedical Research · doi:10.1006/cbmr.1996.0014 · Cited by 10,913
Cortical Surface-Based Analysis
Dale, A. M., Fischl, B., & Sereno, M. I. (1999) · NeuroImage · doi:10.1006/nimg.1998.0395 · Cited by 10,910
Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion
Power, J. D., Barnes, K. A., Snyder, A. Z., Schlaggar, B. L., & Petersen, S. E. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.10.018 · Cited by 7,429
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 3×
“, 2015), end of life anxiety (Gasser et al., 2014a; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), obsessive compulsive disorder (Moreno et al.”
From circuits to behaviour in the amygdala
Janak, P. H., & Tye, K. M. (2015) · Nature · doi:10.1038/nature14188 · Cited by 2,011 · cited 1×
“The amygdala is a complex subcortical structure that is sensitive to emotional stimuli (Janak and Tye, 2015; Sergerie et al., 2008).”

Show all 57 references

Sorted by citations

REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Self-citation
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Self-citation
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
The entropic brain - revisited
Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.03.010 · Cited by 522
Self-citation
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354
“In addition to the more recent clinical research, the reassuring results from these epidemiological data also increase interest in the evaluation of psilocybin as a potential therapeutic medicine (Roseman et al., 2017; Rucker et al., 2017).”
Psychedelic Psychiatry’s Brave New World
Nutt, D., Erritzøe, D., & Carhart-Harris, R. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.020 · Cited by 339
Self-citation
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Gregorio, D. D., Aguilar‐Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1659-20.2020 · Cited by 279
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 279
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895520 · Cited by 208
Self-citation
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Wolff, M., Evens, R., Mertens, L. J., Koslowski, M., Betzler, F., Gründer, G., & Jungaberle, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00005 · Cited by 205
Classic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 119
Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation
Zeifman, R. J., Wagner, A. C., Watts, R., Kettner, H., Mertens, L. J., & Carhart-Harris, R. L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00782 · Cited by 106
“, interpreted as an increase in emotional responsiveness) 1-day post-treatment, which were predictive of decreases in depression severity 5-weeks later (88).”
Self-citation
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 113
Self-citation
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity
Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.12.007 · Cited by 96
Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
Metaxa, A.-M., & Clarke, M. J. (2024) · BMJ · doi:10.1136/bmj-2023-078084 · Cited by 107
Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
Depression, mindfulness, and psilocybin: possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. a review
Heuschkel, K., & Kuypers, K. P. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00224 · Cited by 86
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution
Stoliker, D., Egan, G. F., Friston, K. J., & Razi, A. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000508 · Cited by 96
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C., Modlin, N. L., & Rucker, J. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 94
Serotonin 2A Receptor (5-HT 2A R) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants
Duan, W., Cao, D., Wang, S., & Cheng, J. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00375 · Cited by 81
Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review
Romeo, B., Hermand, M., Pétillion, A., Karila, L., & Benyamina, A. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.002 · Cited by 76
Rapid-acting antidepressants
Witkin, J. M., Martin, A. E., Golani, L. K., Xu, N. Z., & Smith, J. L. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.002 · Cited by 80
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
Modulation of Social Cognition via Hallucinogens and “Entactogens”
Preller, K. H., & Vollenweider, F. X. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00881 · Cited by 71
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Ancient Roots of Today’s Emerging Renaissance in Psychedelic Medicine
George, D. R., Hanson, R., Wilkinson, D., & Garcia‐Romeu, A. (2021) · Culture Medicine and Psychiatry · doi:10.1007/s11013-021-09749-y · Cited by 84
Classical Psychedelics as Therapeutics in Psychiatry – Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders
Mertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change
Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.105 · Cited by 68
Self-citation
Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities
Yaden, D. B., Johnson, M. W., Griffiths, R. R., Doss, M. K., Garcia‐Romeu, A., Nayak, S. M., Gukasyan, N., Mathur, B. N., & Barrett, F. S. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab026 · Cited by 69
The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
Glazer, J. E., Murray, C. H., Nusslock, R., Lee, R., & de Wit, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01479-y · Cited by 56
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
dos Santos, R. G., Hallak, J. E., Baker, G., & Dursun, S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120986422 · Cited by 55
Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm
Perkins, D., Sarris, J. J., Rossell, S. L., Bonomo, Y. A., Forbes, D., Davey, C. G., Hoyer, D., Loo, C. K. A., Murray, G., Hood, S. D., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867421998785 · Cited by 55
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding
Effinger, D. P., Quadir, S. G., Ramage, M. C., Cone, M. G., & Herman, M. A. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02414-5 · Cited by 51
Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality.
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47
Self-citation
Psychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47
Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers
Rocha, J. M., Rossi, G. N., Osório, F. D. L., Bouso, J. C., Silveira, G. D. O., Yonamine, M., Campos, A. C., Bertozi, G., Hallak, J. E. C., & SANTOS, R. G. D. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001396 · Cited by 50
Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin
Stoliker, D., Novelli, L., Vollenweider, F. X., Egan, G. F., Preller, K. H., & Razi, A. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.01.002 · Cited by 51
Rapid-Acting Antidepressants
Witkin, J. M., Knutson, D. E., Rodriguez, G. J., & Shi, S. X.-Y. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180730104707 · Cited by 45
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression
Shukuroglou, M., Roseman, L., Wall, M. B., Nutt, D., Kaelen, M., & Carhart-Harris, R. L. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221125354 · Cited by 45
Self-citation
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature
Rocha, J. M., Osório, F. D. L., Crippa, J. A. S., Bouso, J. C., Rossi, G. N., Hallak, J. E. C., & SANTOS, R. G. D. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319845774 · Cited by 43
Neuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 43
Self-citation
Toward Mapping Neurobehavioral Heterogeneity of Psychedelic Neurobiology in Humans
Moujaes, F., Preller, K. H., Ji, J. L., Murray, J. D., Berkovitch, L., Vollenweider, F. X., & Anticevic, A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.10.021 · Cited by 38
Increased low-frequency brain responses to music after psilocybin therapy for depression
Wall, M. B., Lam, C., Ertl, N., Kaelen, M., Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.081 · Cited by 44
Self-citation
Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment
Healy, C. J., Lee, K. A., & D'Andrea, W. M. (2021) · Chronic Stress · doi:10.1177/24705470211029881 · Cited by 39
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Increased sensitivity to strong perturbations in a whole-brain model of LSD
Jobst, B., Atasoy, S., Ponce‐Alvarez, A., Sanjuán, A., Roseman, L., Kaelen, M., Carhart-Harris, R. L., Kringelbach, M. L., & Deco, G. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117809 · Cited by 36
Self-citation
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
Castelhano, J., Lima, G., Teixeira, M., Soares, C., Pais, M. L., & Castelo-Branco, M. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739053 · Cited by 41
Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 35
Quality of reporting on psychological interventions in psychedelic treatments: a systematic review
Seybert, C., Schimmers, N., Silva, L., Breeksema, J. J., Veraart, J. K. E., Bessa, B. S., d’Orsi, D., Schoevers, R. A., & Oliveira-Maia, A. J. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00333-x · Cited by 35
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 36
Exploring mechanisms of psychedelic action using neuroimaging
Erritzøe, D., Timmermann, C., Godfrey, K. E. M., Castro-Rodrigues, P., Peill, J. M., Carhart-Harris, R. L., Nutt, D., & Wall, M. B. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00172-3 · Cited by 37
Self-citation
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 37
Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder
Weiss, B., Roseman, L., Giribaldi, B., Nutt, D., Carhart-Harris, R. L., & Erritzøe, D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01253-9 · Cited by 41
Self-citation
Human brain changes after first psilocybin use
Lyons, T., Spriggs, M., Kerkelä, L., Rosas, F. E., Roseman, L., Mediano, P. A. M., Timmermann, C., Oestreich, L., Pagni, B. A., Zeifman, R. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71962-3 · Cited by 30
Self-citation
Can psilocybin be safely administered under medical supervision? A systematic review of adverse event reporting in clinical trials
Roscoe, J., & Lozy, O. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221085222 · Cited by 33
Post-traumatic stress disorder: the role of the amygdala and potential therapeutic interventions – a review
Davis, L. L., & Hamner, M. B. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1356563 · Cited by 37
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 27
Ayahuasca for the Treatment of Depression
Palhano-Fontes, F., Soares, B. L., Coelho, N. L. G., Arcoverde, E., & de Araújo, D. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_277 · Cited by 26
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors
Ponomarenko, P., Seragnoli, F., Calder, A. E., Oehen, P., & Hasler, G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231155117 · Cited by 31
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 31
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Chisamore, N., Johnson, D. E., Chen, M. J. Q., Offman, H., Chen-Li, D. C. J., Kaczmarek, E. S., Doyle, Z., McIntyre, R. S., & Rosenblat, J. D. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.051 · Cited by 32
Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis
Irizarry, R., Winczura, A., Dimassi, O., Dhillon, N., Minhas, A., & Larice, J. (2022) · Cureus · doi:10.7759/cureus.31796 · Cited by 26
Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 32
Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230751 · Cited by 27
Self-citation
Don’t be afraid, try to meditate- potential effects on neural activity and connectivity of psilocybin-assisted mindfulness-based intervention for social anxiety disorder: A systematic review
Felsch, C. L., & Kuypers, K. P. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104724 · Cited by 25
Computational chemoproteomics to understand the role of selected psychoactives in treating mental health indications
Fine, J. A., Lackner, R. M., Samudrala, R., & Chopra, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49515-0 · Cited by 25
Psychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 32
Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology
Shinozuka, K., Jerotic, K., Mediano, P. A. M., Zhao, A. T., Preller, K. H., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03187-1 · Cited by 28
Self-citation
Distinct antidepressant therapies act on a common brain network
Ji, G., Xu, W., Zhang, J., Li, Q., Yang, Y., He, K., Yu, F., Zhu, C., Jiang, X. C., Jing, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67945-5 · Cited by 21
The psychedelic renaissance: the next trip for psychiatry?
Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V. (2019) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2019.39 · Cited by 21
Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor
Harari, R., Chatterjee, I., Getselter, D., & Elliott, E. (2024) · iScience · doi:10.1016/j.isci.2024.109686 · Cited by 21
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 21
Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality
Solaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 22
Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation
Barrett, F. S., Zhou, Y., Carbonaro, T. M., Roberts, J., Smith, G. S., Griffiths, R. R., & Wong, D. F. (2022) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.784576 · Cited by 20
Functional MRI markers for treatment-resistant depression: Insights and challenges
Kotoula, V., Evans, J. W., Punturieri, C., Johnson, S. C., & Zarate, C. A. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.04.001 · Cited by 16
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 20
The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
Gill, H., Puramat, P., Patel, P., Gill, B., Marks, C. A., Rodrigues, N. B., Castle, D., Cha, D. S., Mansur, R. B., Rosenblat, J. D., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114577 · Cited by 16
Acute psilocybin increased cortical activities in rats
Liu, J., Wang, Y., Xia, K., Wu, J., Zheng, D., Cai, A., Yan, H., & Su, R. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1168911 · Cited by 17
Retracted
Psychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2020) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.94 · Cited by 16
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
Pouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans
Berkovitch, L., Fauvel, B., Preller, K. H., & Gaillard, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106239 · Cited by 16
Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 16
The Algorithmic Agent Perspective and Computational Neuropsychiatry: From Etiology to Advanced Therapy in Major Depressive Disorder
Ruffini, G., Castaldo, F., Lopez-Sola, E., Sanchez-Todo, R., & Vohryzek, J. (2024) · Entropy · doi:10.3390/e26110953 · Cited by 20
The impact of obesity‐related neuroinflammation on postpartum depression: A narrative review
da Cruz, K. L. D. O., Salla, D. H., de Oliveira, M. P., da Silva, L. E., Vedova, L. M. D., Mendes, T. F., Bressan, C. B. C., Costa, A. B., da Silva, M. R., Réus, G. Z., et al. (2022) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10198 · Cited by 14
Stress-Activated Protein Kinase JNK Modulates Depression-like Behaviors in Mice
Zhou, X., Yi, W., Zhi, Y.-Q., Yu, J., Lu, D., Luo, Z.-S., Yuan, L., Chen, L.-Y., Xu, Z., & Xu, D. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03209-x · Cited by 14
Cognitive, Behavioral, and Circadian Rhythm Interventions for Insomnia Alter Emotional Brain Responses
Leerssen, J., Aghajani, M., Bresser, T., Rösler, L., Winkler, A. M., Foster‐Dingley, J. C., & Someren, E. J. W. V. (2023) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2023.03.007 · Cited by 15
Increased reactivity of the paraventricular nucleus of the hypothalamus and decreased threat responding in male rats following psilocin administration
Effinger, D. P., Hoffman, J. L., Mott, S., Magee, S. N., Quadir, S. G., Rollison, C. S., Toedt, D., Sanchez, M. E., High, M. W., Hodge, C. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49741-9 · Cited by 16
Postpartum depression: A role for psychedelics?
Jairaj, C., & Rucker, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221093793 · Cited by 16
Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers
Rossi, G. N., Rocha, J. M., Osório, F. D. L., Bouso, J. C., Oña, G., Silveira, G. D. O., Yonamine, M., Bertozi, G., Crevelin, E. J., Queiroz, M. E. C., et al. (2023) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001691 · Cited by 14
Emotion regulation effects of Ayahuasca in experienced subjects during implicit aversive stimulation: An fMRI study
Sanchez, T. A., Ramos, L. R., Araujo, F., Schenberg, E. E., Yonamine, M., Lobo, I., de Araújo, D. B., & Luna, L. E. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117430 · Cited by 14
Psychedelics and connectedness to natural and social worlds: An examination of the evidence and a proposed conceptual framework
Forstmann, M., & Sagioglou, C. (2025) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2025.101992 · Cited by 15
Psychedelics, entactogens and psychoplastogens for depression and related disorders
Hoyer, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70088 · Cited by 17
5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity
Germann, C. B. (2019) · Activitas Nervosa Superior · doi:10.1007/s41470-019-00063-y · Cited by 14

Authors: Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L.
Affiliations: Imperial College London (GB)
Corresponding author: Roseman, Leor
ORCID: Roseman, Leor
Demetriou, Lysia
Wall, Matthew B.
Nutt, David J.
Carhart-Harris, Robin L.
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2018-11
Volume: 142
Pages: 263-269
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2017.12.041
OpenAlex: W2781340150
Cited by: 230
References: 57
Citations by year: 2026: 30 · 2025: 34 · 2024: 38 · 2023: 30 · 2022: 34 · 2021: 27 · 2020: 18 · 2019: 10 · 2018: 8
FWCI: 12.42
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Neuropharmacology (publishedVersion, cc-by)
PubMed (publishedVersion)
Spiral (Imperial College London) (submittedVersion, cc-by)
Funders: Imperial College Scholarship Scheme
Imanova
Edmund J Safra Foundation (P17264)
Alex Mosely Charitable Trust (G30444)
MRC clinical development scheme (MR/J00460X/1)
Alex Mosley Charitable Trust
COMPASS group (I30006)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords: psilocybin, treatment-resistant depression, amygdala, emotional face processing, fearful faces, happy faces, psychological support, selective serotonin reuptake inhibitors, antidepressant mechanism, emotional responsiveness
MeSH terms: Facial Recognition, Adult, Amygdala, Antidepressive Agents, Brain Mapping, Combined Modality Therapy, Emotions, Female, Hallucinogens, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Prognosis, Psilocybin, Psychotherapy, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks